For investors looking to cash in on a burgeoning ear therapy space, the latest biotech angling for a public debut could be music to their ears.
Fresh off a $105 million raise in March, ear gene therapy company Akouos is looking for another $100 million for a chance to dance on the Nasdaq well before its lead product enters the clinic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,